Showing results (101-110 of 210) with videos related to

Sort By:
Pageof 21
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 16, 2017
BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing CommitteeSarah A Holstein, Hervé Avet-Loiseau, Theresa Hahn, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2023
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple MyelomaMaría-Victoria Mateos, Ajai Chari, Saad Z Usmani, et al.
Leukemia & Lymphoma|April 29, 2016
A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantationKatja Weisel, Chantal Doyen, Meletios Dimopoulos, et al.
Clinical Drug Investigation|November 25, 2021
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaKatja Weisel, Thomas Martin, Amrita Krishnan, et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion|June 5, 2013
Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple MyelomaBritta Auel, Hartmut Goldschmidt, Thomas Geer, et al.
Oncoimmunology|October 6, 2018
The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myelomaMohamed H S Awwad, Katharina Kriegsmann, Julian Plaumann, et al.
Blood Cancer Journal|August 12, 2024
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigmCharlotte Pawlyn, Fredrik H Schjesvold, David A Cairns, et al.
The Lancet. Haematology|March 15, 2020
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trialMarc S Raab, Monika Engelhardt, Antje Blank, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 3, 2020
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTORMaria-Victoria Mateos, Pieter Sonneveld, Vania Hungria, et al.
The Lancet. Oncology|August 28, 2017
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Hartmut Goldschmidt, Ruben Niesvizky, et al.
Pageof 21